In relation to pathology, this study identified challenges related to four areas: 1) selecting, performing, and interpreting biomarker tests, including those specific to RET; 2) communication and collaboration structures to support decision-making; 3) perception of clinical trials for RET inhibitors; and 4) barriers associated with government regulations on treatments and genomic testing for lung and thyroid cancers. The gene discussed is RET; the disease is thyroid gland carcinoma.